Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis
Table 1
Demographic data and baseline characteristics of the RA patients treated with methotrexate (MTX) or its combination with azilsartan (Azil).
Parameters
MTX + placebo
MTX + Azil
value
Gender
Male (%)
8 (32)
12 (40)
0.62
Female (%)
17 (78)
18 (60)
0.53
Age (years)
Body weight (Kg)
BMI (Kg/m2)
Disease duration (year)
MTX treatment (months)
ESR (mm/hr)
hsCRP (μg/ml)
DAS-28 score (4 values)
SDAI score
HAQ-DI score
CDAI score
Joint deformities (%)
4 (16.0)
5 (16.7)
0.48
Use of steroids (%)
3 (12)
4 (13.3)
0.5
Use of NSAIDs (%)
2 (8)
2 (6.7)
0.61
Associated diseases
Hypertension (%)
4 (16.0)
6 (20.0)
0.12
Diabetes mellitus (%)
3 (12.0)
2 (6.7)
0.11
Values are presented as mean ± S.D or percentage; n: number of patients; MTX: methotrexate; Azil: azilsartan; NSAIDs: nonsteroidal anti-inflammatory drugs.
